Oral Minoxidil Shows Promise for Hair Loss in Women

A new study compares the efficacy of oral versus topical minoxidil for treating female pattern hair loss.

Updated on Oct. 30, 2026 in Women’s Health

Bold vector editorial illustration featuring a clinical lens focusing on a single hair fiber, representing dermatological research. — A retrospective study of 128 women published this week suggests that low-dose oral minoxidil outperforms topical foam for female pattern hair loss. AI Illustration. Upload story photo >

Live Poll

Do you trust that medical treatments effectively prevent further hair loss?

A retrospective cohort study involving 128 women finds that low-dose oral minoxidil may be more effective than topical foam at slowing hair loss progression. Results indicate that oral treatment significantly reduces the rate of disease progression compared to topical application.

Why it matters

Female pattern hair loss is a common condition that can affect quality of life, making the identification of superior treatment options a clinical priority. This data provides a direct comparison between two standard delivery methods to help guide therapeutic choices.

In a study of 128 women, those treated with oral minoxidil saw an average Sinclair score improvement of 0.30 points, compared to a 0.20 point improvement for those using 5% topical foam. Stabilization rates were nearly identical between the two groups.

The players

Journal of the American Academy of Dermatology

This is a leading peer-reviewed medical journal that publishes original research and clinical studies relevant to skin health and dermatological treatments.

The details

Researchers in Burlington, Massachusetts, used blinded raters to score standardized scalp photographs of study participants to ensure accuracy. A board-certified dermatologist provided oversight to resolve any scoring disagreements between the raters.

October 29, 2026: Study results are published in the Journal of the American Academy of Dermatology.

Health Landscape

This research marks a departure from the traditional use of topical minoxidil as the primary FDA-approved standard for non-prescription hair loss treatment. It reflects a broader shift toward examining systemic applications for chronic dermatological conditions.

Patients currently managing hair loss may see changes in their treatment options as doctors evaluate these findings regarding oral versus topical methods. It is important to consult a healthcare provider to discuss whether oral minoxidil is an appropriate clinical choice.

The takeaway

These findings suggest that systemic treatment may offer better stabilization against the progression of hair loss in some patients. Patients should discuss the clinical balance of benefits and risks with their dermatologist before changing their existing hair care routine.